Elevated Expression of BIRC6 Protein in Non–Small-Cell Lung Cancers is Associated with Cancer Recurrence and Chemoresistance

Introduction: Non–small-cell lung cancer (NSCLC) is an aggressive, highly chemoresistant disease. Reliable prognostic assays and more effective treatments are critically required. BIRC6 (baculoviral inhibitors of apoptosis proteins repeat-containing 6) protein is a member of the inhibitors of apoptosis protein family thought to play an important role in the progression or chemoresistance of many cancers. In this study, we investigated whether BIRC6 expression can be used as a prognostic marker or potential therapeutic target for NSCLC. Methods: In a retrospective analysis, BIRC6 protein expression was determined for 78 resected primary NSCLCs and nine benign lung tissues. Twenty-nine chemoresistant or chemosensitive subrenal capsule NSCLC tissue xenografts were assessed for BIRC6 expression, using immunohistochemistry, and 13 of them for BIRC6 gene copy number, using array comparative genomic hybridization analysis. The effect of small interfering RNA–induced BIRC6 knockdown on the growth of human NSCLC cell cultures and apoptosis (in combination with cisplatin) was investigated. Results: Elevated BIRC6 protein expression in NSCLC tissues was associated with poor 3-year relapse-free patient survival, lymph node involvement, and advanced pathological tumor, node, metastasis stage. In patient-derived lung squamous cell carcinoma xenografts, chemoresistance was associated with elevated BIRC6 expression and increased gene copy number. Small interfering RNA–induced BIRC6 down-regulation inhibited growth of the NSCLC cells and sensitized the cells to cisplatin. Conclusions: BIRC6 may play an important role in the malignant progression and chemoresistance of NSCLC. Elevated BIRC6 protein expression may serve as a predictive marker for chemoresistance of NSCLCs and a poor prognostic factor for NSCLC patients. Down-regulation of the BIRC6 gene as a therapeutic approach may be effective, especially in combination with conventional chemotherapeutics.

[1]  Hee-Jin Kim,et al.  Overexpression of Apollon, an Antiapoptotic Protein, Is Associated with Poor Prognosis in Childhood De novo Acute Myeloid Leukemia , 2007, Clinical Cancer Research.

[2]  Matthias Mann,et al.  Proteomic Changes Resulting from Gene Copy Number Variations in Cancer Cells , 2010, PLoS genetics.

[3]  G. Silvestri,et al.  One hundred years of lung cancer. , 2005, American journal of respiratory and critical care medicine.

[4]  L. Stewart,et al.  Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data , 2010, The Lancet.

[5]  J. Jass,et al.  Value of staining intensity in the interpretation of immunohistochemistry for tumor markers in colorectal cancer , 2007, Virchows Archiv.

[6]  Bradley P. Coe,et al.  Differential disruption of cell cycle pathways in small cell and non-small cell lung cancer , 2006, British Journal of Cancer.

[7]  D. Fabbro,et al.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. , 2000, Cancer research.

[8]  D. Hallahan,et al.  Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma , 2005, Cancer.

[9]  C. Magi-Galluzzi,et al.  The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation. , 2007, Clinical genitourinary cancer.

[10]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  W. Skarnes,et al.  The Birc6 (Bruce) gene regulates p53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Yi Li Yang,et al.  The IAP family: endogenous caspase inhibitors with multiple biological activities , 2000, Cell Research.

[13]  T. Tsuruo,et al.  A human IAP-family gene, apollon, expressed in human brain cancer cells. , 1999, Biochemical and biophysical research communications.

[14]  Jeffrey P. Mower,et al.  Multiple major increases and decreases in mitochondrial substitution rates in the plant family Geraniaceae , 2005, BMC Evolutionary Biology.

[15]  Bradley P. Coe,et al.  A tiling resolution DNA microarray with complete coverage of the human genome , 2004, Nature Genetics.

[16]  C. Day,et al.  Assembling the building blocks: structure and function of inhibitor of apoptosis proteins , 2010, Cell Death and Differentiation.

[17]  W. Lam,et al.  DNA Extraction from Paraffin Embedded Material for Genetic and Epigenetic Analyses , 2011, Journal of visualized experiments : JoVE.

[18]  S. Jentsch,et al.  Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin ligase. , 2004, Molecular cell.

[19]  P. Carinci,et al.  Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. , 2006, International journal of oncology.

[20]  C. Qian,et al.  Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil , 2008, Gene Therapy.

[21]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[22]  B. Szende,et al.  Molecular Profiling of Parathyroid Hyperplasia, Adenoma and Carcinoma , 2012, Pathology & Oncology Research.

[23]  Rabab Kreidieh Ward,et al.  BMC Bioinformatics Methodology article A stepwise framework for the normalization of array CGH data , 2005 .

[24]  M. Daidone,et al.  Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation , 2009, British Journal of Cancer.

[25]  S. Lam,et al.  Patient-Derived First Generation Xenografts of Non–Small Cell Lung Cancers: Promising Tools for Predicting Drug Responses for Personalized Chemotherapy , 2010, Clinical Cancer Research.

[26]  A. Gazdar,et al.  Apoptosis and lung cancer: A review , 2003, Journal of cellular biochemistry.

[27]  Calum MacAulay,et al.  SIGMA2: A system for the integrative genomic multi-dimensional analysis of cancer genomes, epigenomes, and transcriptomes , 2008, BMC Bioinformatics.

[28]  R. Ng,et al.  Multiple Aberrations of Chromosome 3p Detected in Oral Premalignant Lesions , 2008, Cancer Prevention Research.

[29]  Hui-Chen Hsu,et al.  Regulation of apoptosis proteins in cancer cells by ubiquitin , 2004, Oncogene.

[30]  T. Noda,et al.  Apollon ubiquitinates SMAC and caspase-9, and has an essential cytoprotection function , 2004, Nature Cell Biology.

[31]  S. Hatakeyama,et al.  YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model , 2011, Anti-cancer drugs.

[32]  Yaqoub Ashhab,et al.  The inhibitor of apoptosis protein family (IAPs): an emerging therapeutic target in cancer. , 2004, Seminars in cancer biology.

[33]  Calum MacAulay,et al.  Integrative Genomic Analyses Identify BRF2 as a Novel Lineage-Specific Oncogene in Lung Squamous Cell Carcinoma , 2010, PLoS medicine.

[34]  R. deLeeuw,et al.  Cytogenetically balanced translocations are associated with focal copy number alterations , 2007, Human Genetics.

[35]  E. Waxman.  Advances in chemotherapy for non-small cell lung cancer. , 2008, Seminars in oncology nursing.

[36]  The Birc 6 ( Bruce ) gene regulates p 53 and the mitochondrial pathway of apoptosis and is essential for mouse embryonic development , 2005 .

[37]  Bradley P. Coe,et al.  FACADE: a fast and sensitive algorithm for the segmentation and calling of high resolution array CGH data , 2010, Nucleic acids research.

[38]  A. Adly,et al.  BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis , 2012, European journal of haematology.

[39]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[40]  H. Clevers,et al.  Comparative Proteomics of Colon Cancer Stem Cells and Differentiated Tumor Cells Identifies BIRC6 as a Potential Therapeutic Target* , 2011, Molecular & Cellular Proteomics.

[41]  V. Dragowska,et al.  Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  Pascal Meier,et al.  IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer , 2010, Nature Reviews Cancer.

[43]  B. Stewart,et al.  World Cancer Report , 2003 .

[44]  B. Yalcin,et al.  Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.

[45]  W. Fairbrother,et al.  The Inhibitor of Apoptosis Proteins as Therapeutic Targets in Cancer , 2007, Clinical Cancer Research.

[46]  Yih-Leong Chang,et al.  Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction , 2011, PloS one.

[47]  A. Schimmer.  Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice , 2004, Cancer Research.

[48]  P. Boyle,et al.  World Cancer Report 2008 , 2009 .

[49]  Bradley P. Coe,et al.  DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers , 2008, Oncogene.